Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05607732 · ClinicalTrials.gov registry record · NA

Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial

A NA study of Alzheimer Disease and Dementia, sponsored by Northwestern University.

Recruiting
Registry status
NA
Development phase
45,257
Enrollment target
1
Study location

NCT05607732: Recruiting NA study of Alzheimer Disease and Dementia, sponsored by Northwestern University.

NCT05607732 is a NA study of Alzheimer Disease and Dementia that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 45,257 participants, above the 2,603-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (1639% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05607732, a NA study of Alzheimer Disease and Dementia, is actively recruiting participants, sponsored by Northwestern University.

RECRUITING
Registry status
NA
Development phase
45,257 participants
Enrollment target
1
Study location

Study Summary

Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and caregivers. We will conduct a clinic-randomized, pragmatic trial testing the effectiveness and fidelity of our NIH Toolbox-derived paradigm to improve early detection and management of cognitive impairment/dementia in primary care settings serving health disparate patient populations.

Primary Outcome

This will be operationalized as either results of an administered cognitive test suggesting impairment ('detected') or having any relevant International Classification of Diseases (ICD) 10 code recorded in a patient's record after the trial launch date and throughout follow-up observation period ('diagnosis').

Interventions

  • DIAGNOSTIC_TEST MyCog

Study Locations (1)

Illinois

  • Oak Street Health - Chicago

Trial Details

FieldValue
Enrollment Target 45,257 participants
Start Date 2024-01-30
Est. Completion 2027-07-07
Phase NA
Northwestern University

1,209 total trials

What NCT05607732 shows while recruiting

NCT05607732 is an interventional study that assigns participants to a tested intervention. Its 45,257 participants enrollment target places it among the larger protocols in the corpus, above the 2,603-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (1639% higher).

The record links to 4 conditions, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which MyCog is the first listed.

NCT05607732 reports a single indexed study location in Illinois.

Frequently Asked Questions

What is clinical trial NCT05607732 about?

NCT05607732 is a clinical study titled "Primary Care Detection of Cognitive Impairment Leveraging Health & Consumer Technologies in Underserved Communities: The MyCog Trial". Our study intends to offer 'real world' evidence of a viable, sustainable means to mobilize primary care via a comprehensive strategy for detecting cognitive impairment and dementias, advancing next steps for referral, and participating in the care planning and management of affected patients and ca...

What is the current status of trial NCT05607732?

This trial is currently recruiting. It is a NA study. The enrollment target is 45,257 participants. The study started on 2024-01-30. Estimated completion is 2027-07-07.

What conditions does trial NCT05607732 study?

This clinical trial studies the following conditions: Alzheimer Disease, Dementia, Cognitive Impairment, Cognitive Decline.

What interventions are being tested in trial NCT05607732?

The interventions under investigation include: MyCog (DIAGNOSTIC_TEST).

Who is sponsoring clinical trial NCT05607732?

This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05607732 being conducted?

This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Alzheimer Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT05607732's enrollment target sits among peer trials

45,257 4th of 306 higher than 303 of 306 other Alzheimer Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06824350 · 45,450 participants · NA

    Clean Trial - Chlorination to Reduce Enteric and Antibiotic Resistant Infections in Neonates

  • NCT06597968 · 45,991 participants

    Evaluating the Real World Performance of an AI Based Lung Nodule Detection Tool

  • NCT03977402 · 47,500 participants

    Total Cancer Care Protocol: A Lifetime Partnership With Patients Who Have or May be at Risk of Having Cancer

  • NCT06655974 · 48,000 participants · NA

    Predictive Modeling for Social Needs in Emergency Department Settings

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05607732, the US trial registry maintained by the National Library of Medicine. NCT05607732 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.